Towards personalized, tumour-specific, therapeutic vaccines for cancer

By Zhuting Hu, P. Ott, Catherine J. Wu. Nature reviews. Immunology, 2017

909 citations recorded by the source corpus.

Cancer vaccines, which are designed to amplify tumour-specific T cell responses through active immunization, have long been envisioned as a key tool of effective cancer immunotherapy. Despite a clear rationale for such vaccines, extensive past efforts were unsuccessful in mediating clinically relevant antitumour activity in humans. Recently, however, next-generation sequencing and novel bioinformatics tools have enabled the systematic discovery of tumour neoantigens, which are highly desirable immunogens because they arise from somatic mutations of the tumour and are therefore tumour specific. As a result of the diversity of tumour neoepitopes between individuals, the development of personalized cancer vaccines is warranted. Here, we review the emerging field of personalized cancer vaccination and discuss recent developments and future directions for this promising treatment strategy.

Subfields: Immunology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/90eed69992cc23c46d4dcb125915c7b1566ec709

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Sandra Hervás-Stubbs
2. I. Melero
3. Aviv Regev
4. G. Getz
5. Catherine J. Wu
6. S. Shukla
7. P. Ott
8. Nir Hacohen

In Molecular Biology

1. Aviv Regev
2. Eric S. Lander
3. Stacey Gabriel
4. P. Wen
5. Catherine J. Wu
6. Niall J. Lennon
7. Nir Hacohen
8. K. Livak

In Oncology

1. I. Melero
2. Catherine J. Wu
3. P. Ott
4. Eric S. Lander
5. Nicholas McGranahan
6. Charles Swanton

Citations in the corpus

• Neoantigens: promising targets for cancer therapy (2023, background): “Compared with other types of tumor antigens, such as cancertestis antigens (CTAs) and TAAs, neoantigens offer a distinct advantage in their unique tumor-specific and absence in normal tissues, presenting ideal targets for effectively personalized treatment of tumors (Table 1).(25,26) Notably, T cell”
• Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies (2022, background): “Vaccines also contain components designed to activate DCs that have been pulsated with antigens and direct them to a local lymph node, for example, the DC vaccination and OncoVAX [135].”
• Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial (2018, methodology): “Next, we defined expression scores, for each cell, for the following genes and signatures, based on the average E of the gene(s) indicated in parenthesis: (1) CD4 (CD4); (2) CD8 (CD8A and CD8B); (3) regulatory T (Treg) cells (FOXP3 and IL2RA); (4) cytotoxic T cells (PRF1, GZMA, GZMK, NKG7 and CST7);”
• Advances in immunotherapy for hepatocellular carcinoma (2021, background): “I.M. receives funding from MINECO SAF2014-52361-R and SAF 2017- 83267-C2-1R; Worldwide Cancer Research Grant (15-1146); the Asociacion Española Contra el Cancer (AECC) Foundation under grant GCB15152947MELE; and the European Union’s Horizon 2020 Program (grant agreement no. 635122 PROCROP).”